Rolinsatamab (CAS: 2095467-30-2)
Rolinsatamab is an IgG1κ chimeric monoclonal antibody targeting the prolactin receptor (PRLR). It can be conjugated with the pyrrolobenzodiazepine (PDB) dimer SGD-1882 via a cleavable linker, forming the antibody-drug conjugate (ADC) Rolinsatamab talirine. This ADC features two site-specific drug attachments at cysteines (C242, C242′) and a cathepsin B-cleavable linker.
Key Features:
- Target Specificity: Binds to PRLR.
- Mechanism of Action: Conjugated to SGD-1882, releasing the cytotoxic drug in PRLR-positive cells through a cathepsin B-cleavable linker.
- Therapeutic Potential: Investigated for treating PRLR-positive cancers.
Applications:
- Cancer Research: Used in the development of Rolinsatamab talirine for targeted cancer therapy.
- Therapeutic Development: Explored as a treatment for cancers expressing PRLR.
- Inflammatory Disease Research: Studied for its potential in immune modulation.
Handling and Storage:
- Formulation: Available as a research-grade biosimilar antibody.
- Storage: Store at -20°C, protected from light.
- Precautions: Use personal protective equipment and ensure proper ventilation.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
